FDA approval is a reassuring phrase. It suggests someone serious has checked the homework. For people with commercial insurance, it can also feel like a ticket: approved treatment, good plan, done. Unfortunately, several beliefs about FDA status are only half true, and the other half tends to show up as a surprise bill or a denied claim.

Here are seven common myths, checked against how approval and insurance actually work. Where useful, we lean on a poll we commissioned, 443 adults drawn from ten Midwest states, whose final, validated results we cite.

Myth 1: "Most people don't really care whether something is FDA-approved"

False. In our poll, FDA approval rated as a big or deciding consideration for 59 percent of respondents weighing a new depression treatment. Another 27 percent said it would matter somewhat. Just 14 percent said it would not matter at all. If FDA status is on your mind, you are thinking like most people.

Myth 2: "If it's FDA-approved, my plan has to cover it"

False. FDA approval and insurance coverage are separate decisions made by separate organizations. The FDA decides whether a drug can be marketed for a given use. Your insurer decides whether, and under what conditions, it will pay.

For approved depression treatments, commercial plans commonly require prior authorization. They may require step therapy, meaning you try other treatments first. They may limit coverage to certain providers. What approval usually does is give you a clearer path to coverage than an off-label treatment would have. It does not skip the path.

Practical step: request your insurer's written coverage policy for the exact treatment you are considering. It lists exactly what your doctor needs to document.

Myth 3: "FDA-approved means it will work for me"

False. Approval means the FDA found the evidence showed benefits outweigh risks for a particular group of patients. Clinical trials report averages and the share of participants who responded. Some people in any trial improve a lot, some a little, and some not at all. Approval tells you a treatment has been studied and judged worthwhile for a population. It cannot tell you how you will respond. That is a conversation for your clinician.

Myth 4: "Anything that isn't FDA-approved for depression is illegal or a scam"

False, but caution is still warranted. A doctor may lawfully prescribe an approved drug for a use its label does not list. Medicine calls this off-label prescribing, and it happens in every specialty. IV ketamine is a case in point: its approval is for anesthesia, so depression treatment falls off-label.

That said, off-label means no FDA review of the evidence for that purpose, and commercial plans often refuse to pay for it. Compounded products, like many at-home ketamine lozenges, lack FDA approval entirely, and the agency has cautioned the public about compounded ketamine taken with no one watching. Legal and approved are not the same thing.

Myth 5: "All the ketamine treatments I keep hearing about are FDA-approved"

False. Only one member of the ketamine family is FDA-approved for depression: esketamine, sold as Spravato. Its label is for depression that earlier treatment has not relieved, and the spray is used only inside a certified healthcare setting, followed by a monitored wait of two hours or longer. Brain Recovery Centers describes what a Spravato appointment involves. Other ketamine offerings for depression are off-label or compounded.

Our poll found 73 percent unfamiliar with Spravato entirely, 21 percent who recognized the word without knowing the drug, and 6 percent able to describe it. So when a clinic advertises "ketamine therapy," it is worth asking exactly which kind.

Myth 6: "FDA-cleared is a watered-down version of approved"

Misleading. The terms reflect different pathways. Drugs are approved. Many medical devices are cleared, a process that compares them to devices already on the market. Transcranial magnetic stimulation, or TMS, holds FDA clearance for adult depression that antidepressants have not lifted. That is the normal route for a device, not a lesser grade. Many commercial plans cover TMS with prior authorization.

Myth 7: "Clinics are built around people with commercial insurance"

Only partly true. Commercial coverage was the most common type in our survey, but only just. Asked to select all the coverage they have, 39 percent of respondents reported commercial insurance and 37 percent reported Medicaid, a near tie, with Medicare at 23 percent. A clinic that took only one kind of plan would miss a large share of patients, so networks vary plan by plan. For you, this means one thing: never assume a clinic is in network with your specific plan. Ask them to verify benefits for your plan, for the exact service, before you start.

A bonus myth: "The clinic will sort out the insurance for me"

Sometimes true, never certain. Good clinics verify benefits and file prior authorizations. But you are the one who receives the bill, so it pays to confirm the details yourself. Ask for your estimated share in writing, and keep a note of who you spoke to and when.

What to take from this

FDA status is a useful first filter. It tells you something about the evidence and often something about the coverage path. But it does not promise payment, results, or fit. A short checklist:

  • Ask your doctor whether a treatment is approved, cleared, off-label, or compounded for your condition.
  • Ask whether your history matches the approved use.
  • Ask your plan for the coverage policy and whether it runs through the medical or pharmacy benefit.
  • Get a written estimate for the whole course.

Your own doctor is the natural place to start. Of everyone we surveyed, 74 percent told us that a nod from the doctor who knows them would be enough to try a new treatment.

These myth checks are general information, not medical advice, and whether a treatment suits you depends on a clinician who has reviewed your history.

If thoughts of suicide are with you, an authorization or appointment can wait. Use 988, by phone or by text, and the Suicide and Crisis Lifeline will connect you with a real person at any hour, free.

Methodology

Pollfish's consumer panel carried the survey, and collection stopped on June 23, 2026. All 443 of its respondents, each 18 to 64, lived in Illinois, Ohio, Nebraska, Kansas, Indiana, Iowa, Oklahoma, Missouri, Wisconsin, and Minnesota. Because respondents could tick several coverage types, the coverage shares add up to more than the full sample. Every result is final now that validation has wrapped up. Our publisher commissioned this poll and carried its full cost.